{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Satybaldiyeva N"],"funding":["NIDA NIH HHS","NHLBI NIH HHS"],"pagination":["100"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12690965"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(1)"],"pubmed_abstract":["<h4>Background</h4>Since the passage of the 2018 US Farm Bill there has been a market for cannabinoid products derived from Cannabis sativa L. that contain < 0.3% delta-9 tetrahydrocannabinol (THC). Understanding the characteristics and motivations of cannabinoid product users is crucial for appropriate regulation of these products.<h4>Methods</h4>We conducted a cross-sectional survey of 1,523 adults 18 years or older using the probability-based Ipsos KnowledgePanel, representative of 97% of US households. We assessed lifetime use of cannabidiol (CBD), delta-8 THC, cannabinol (CBN), cannabigerol (CBG), and hexahydrocannabinol (HHC), as well as self-reported reasons for using these products (i.e., medical vs. recreational). Using multivariable logistic regression models, we investigated ass"],"journal":["Journal of cannabis research"],"pubmed_title":["Prevalence and reasons for using cannabidiol, delta-8 tetrahydrocannabinol, cannabinol, cannabigerol, and hexahydrocannabinol among US adults."],"pmcid":["PMC12690965"],"funding_grant_id":["T32DA035165","5T32HL161270-03","K01DA054303"],"pubmed_authors":["Satybaldiyeva N","Yang KH","Ferran K","Kepner W","Leas EC"],"additional_accession":[]},"is_claimable":false,"name":"Prevalence and reasons for using cannabidiol, delta-8 tetrahydrocannabinol, cannabinol, cannabigerol, and hexahydrocannabinol among US adults.","description":"<h4>Background</h4>Since the passage of the 2018 US Farm Bill there has been a market for cannabinoid products derived from Cannabis sativa L. that contain < 0.3% delta-9 tetrahydrocannabinol (THC). Understanding the characteristics and motivations of cannabinoid product users is crucial for appropriate regulation of these products.<h4>Methods</h4>We conducted a cross-sectional survey of 1,523 adults 18 years or older using the probability-based Ipsos KnowledgePanel, representative of 97% of US households. We assessed lifetime use of cannabidiol (CBD), delta-8 THC, cannabinol (CBN), cannabigerol (CBG), and hexahydrocannabinol (HHC), as well as self-reported reasons for using these products (i.e., medical vs. recreational). Using multivariable logistic regression models, we investigated ass","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-06T00:30:56.528Z","creation":"2026-05-24T03:11:49.466Z"},"accession":"S-EPMC12690965","cross_references":{"pubmed":["41366718"],"doi":["10.1186/s42238-025-00359-8"]}}